The Panoptix lens was FDA-approved in August 2019, having been used for many years in over 70 countries. It is the first and only “Trifocal Intraocular Lens” and the most advanced IOL that is now available. Panoptix is clinically shown to deliver an exceptional combination of near, intermediate and distance vision, reducing the need for glasses after surgery.
While the lens implant looks like a multifocal lens, the optics work differently. Instead of producing two distinct focal points, the lens uses ENLIGHTEN 9R) Optical Technology, proprietary design that optimizes intermediate vision without compromising near and distance vision.
The lens can achieve excellent clarity at distance and a range of clear vision at near for patients receiving the lens. Before, the light would be split in two ways – for distance and for near, resulting in a potential gap in vision. With the Panoptix trifocal lens, there is no gap.
The Panoptix can correct both spherical and astigmatic corrections, and builds on Alcon’s proven AcrySof IQ IOL platform. With this lens, patients, can achieve excellent clarity at distance and a range of clear vision at near for patients receiving the lens.
The unique technology allows for reading vision that is at a level in between the Symfony and the traditional multifocal lenses. Dr. Rapoport is one of the first group of surgeons in NYC to implement this lens with success in her practice.